High Quality 99% CAS 763113-22-0 Olaparib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Olaparib
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Keep in Cool and Dry Place
• Delivery: Express 5-7 Days Arrive
• Test Method: HPLC
• Assay: 99%
• Shipping Area: Worldwide/All Countries
• CAS: 763113-22-0
• Mf: C24h23fn4o3
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200kg Per Month

Product Description

High Quality 99% CAS 763113-22-0 Olaparib

Specification of Analysis

Items	Standards	Results
Appearance	White or off-white crystalline powder	Complies
Identification	By IR	Complies
	By HPLC	Complies
Solubility	slightly soluble in ethanol, very slightly soluble in water	Complies
Loss on Drying	≤ 1.00%	0.35%
Heavy Metals	≤ 20ppm	Complies
Residue on Ignition	≤ 0.10%	0.06%
Related Substance	Any single impurity: ≤0.10%	0.06%
	Total Impurities: ≤1.00%	0.18%
Assay (HPLC basis on drying)	98.0%~102.0%	99.96%
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool place

Description Function

Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. 

Function

Olaparib as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Olaparib to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.